- Conditions
- RSV Immunization
- Interventions
- RSVt vaccine, Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine, Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine, Hepatitis B vaccine, Streptococcus pneumoniae vaccine, Rotavirus vaccine, Measles, mumps, and rubella vaccine, Varicella virus vaccine, Placebo
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 6 Months to 12 Months
- Enrollment
- 2,226 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Grand Bay, Alabama • Mobile, Alabama + 55 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 264
matching trials from the live ClinicalTrials.gov search.
- Conditions
- RSV Infection
- Interventions
- Nirsevimab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 0 Years to 2 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Tampa, Florida • Syracuse, New York + 4 more
- Conditions
- Participants Less Than 12 Months of Age With RSV Illness
- Interventions
- Motavizumab, Placebo
- Biological · Other
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 0 Months to 12 Months
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 31
- States / cities
- Tucson, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 24 more
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- RSV-F Vaccine, Phosphate Buffer Placebo
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 1,330 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 10
- States / cities
- Redding, California • Stockbridge, Georgia • Lenexa, Kansas + 7 more
- Conditions
- Drug Safety
- Interventions
- MDT-637, Placebo
- Drug
- Lead sponsor
- MicroDose Therapeutx, Inc
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Costa Mesa, California
- Conditions
- Respiratory Syncytial Viruses
- Interventions
- ABRYSVO Vaccination
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 0 Months to 6 Months
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- RSV Infection
- Interventions
- RSV 6120/∆NS2/1030s, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 60 Months
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Respiratory Syncytial Virus Hospitalizations
- Interventions
- Not listed
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- Up to 12 Months
- Enrollment
- 497 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 44
- States / cities
- Little Rock, Arkansas • Loma Linda, California • Long Beach, California + 40 more
- Conditions
- Respiratory Syncytial Virus Prevention
- Interventions
- Ad26.RSV.PreF-based Vaccine
- Biological
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 60 Years to 75 Years
- Enrollment
- 755 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 13
- States / cities
- Athens, Alabama • Vestavia Hills, Alabama • Phoenix, Arizona + 8 more
- Conditions
- RSV Infection
- Interventions
- GS-5806
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- COVID-19 Respiratory Infection, Respiratory Syncytial Virus Infections, Rhinoviral Infections, Influenza Viral Infections
- Interventions
- Not listed
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10,034 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Respiratory Syncytial Virus Infection, Healthy Volunteers, Metapneumovirus Infection
- Interventions
- RSV/hMPV mRNA LNP 1, RSV/hMPV mRNA LNP 2, RSV mRNA LNP 1, hMPV mRNA LNP 1
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 558 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 9
- States / cities
- Gardena, California • Hallandale, Florida • Meridian, Idaho + 6 more
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- Low dose RSV-F Vaccine with Adjuvant, Low dose RSV-F Vaccine without Adjuvant, High dose RSV-F Vaccine with Adjuvant, High dose RSV-F Vaccine without Adjuvant, Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing], Placebo
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 330 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 4
- States / cities
- Anaheim, California • Rockville, Maryland • Mt. Pleasant, South Carolina + 1 more
- Conditions
- SARS CoV 2 Infection, Respiratory Syncytial Virus (RSV), Bronchiolitis, Asthma
- Interventions
- Not listed
- Lead sponsor
- Tulane University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2028
- U.S. locations
- 2
- States / cities
- Metairie, Louisiana • New Orleans, Louisiana
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- VXA-RSV-f Tablets (high dose), VXA Placebo Tablets, VXA-RSV-f Tablets (low dose)
- Biological · Other
- Lead sponsor
- Vaxart
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Melbourne, Florida
- Conditions
- Respiratory Syncytial Virus
- Interventions
- Not listed
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- Up to 6 Months
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 5
- States / cities
- San Diego, California • Lake City, Florida • Woburn, Massachusetts + 2 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV cps2 Vaccine, Placebo Vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 24 Months
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2013
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Laurel, Maryland
- Conditions
- Respiratory Syncytial Virus
- Interventions
- EDP-938, Placebo
- Drug
- Lead sponsor
- Enanta Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Pelham, Alabama • Anaheim, California + 9 more
- Conditions
- Viral Pneumonia
- Interventions
- SNG001, Placebo
- Drug
- Lead sponsor
- Synairgen Research Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Detroit, Michigan + 2 more
- Conditions
- Upper Respiratory Tract Infection
- Interventions
- RSV A2
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Respiratory Syncytial Virus Infection
- Interventions
- Abrysvo, Beyfortus
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 181 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 8
- States / cities
- Atlanta, Georgia • Baltimore, Maryland • New York, New York + 5 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- ALN-RSV01
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Respiratory Syncytial Virus-associated Lower Respiratory Tract Disease Prevention
- Interventions
- RSV preF-based Vaccine, Placebo
- Biological · Drug
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 11
- States / cities
- Long Beach, California • DeLand, Florida • Miami Lakes, Florida + 7 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV vaccine MV-012-968 (dosage #1), RSV vaccine MV-012-968 (dosage #2)
- Biological
- Lead sponsor
- Meissa Vaccines, Inc.
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas